≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at 2-8°C,Protected from light,Desiccated Ships Wet ice Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest , senescence and apoptosis.
In Vitro
Milademetan (DS-3032) can stabilize TP53 and selectively induce CDKNA1, BAX and MDM2 expression in neuroblastoma cells with wild-type TP53. Milademetan (DS-3032b) treatment enhances TP53 target gene expression and induces G1 cell cycle arrest , senescence and apoptosis. Milademetan (DS-3032b, 0-2000 nM) treatment selectively inhibits viability, proliferation and migration of neuroblastoma cells with wildtype TP53 independently of MYCN status . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay Cell Line: SK-N-SH, SH-SY5Y, IMR32, IMR5 and LAN5 cell lines. Concentration: 0-2000 nM. Incubation Time: 24-72 h. Result: Reduced viability in a dose- and time-dependent manner. Exhibited IC50 values of 21.9 nM, 17.7 nM, 52.63 nM, 25.7 nM and 44.1 nM in SK-N-SH, SH-SY5Y, IMR32, IMR5 and LAN5 cell lines, respectively (72 h).
In Vivo
Milademetan (DS-3032b, 50 mg/kg, oral gavage) delays tumor growth and improves survival in mice xenografted with neuroblastoma cells with functional TP53. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SH-SY5Y xenograft tumors in nude mice. Dosage: 50 mg/kg. Administration: Oral gavage for 30 consecutive days with an alternating schedule of 4 days of daily treatment with oral gavages followed by 2 days without treatment (4+2). Result: Survival in the mouse cohort was significantly prolonged. Reduced neuroblastoma xenograft tumor growth by activating TP53 signaling.
Form:Solid
| Canonical Smiles | CC1=CC=C(C=C1)S(=O)(=O)O.CC1(CCC2(CC1)C3(C(C(N2)C(=O)NC4CCC(OC4)C(=O)N)C5=C(C(=NC=C5)Cl)F)C6=C(C=C(C=C6)Cl)NC3=O)C.O |
|---|---|
| InChIKey | WPJOGWGXMTUHPW-CIPNXXNHSA-N |
| INCHI | 1S/C30H34Cl2FN5O4.C7H8O3S.H2O/c1-28(2)8-10-29(11-9-28)30(18-5-3-15(31)13-19(18)37-27(30)41)21(17-7-12-35-24(32)22(17)33)23(38-29)26(40)36-16-4-6-20(25(34)39)42-14-16;1-6-2-4-7(5-3-6)11(8,9)10;/h3,5,7,12-13,16,20-21,23,38H,4,6,8-11,14H2,1-2H3,(H2,34,39)(H,36,40)(H,37,41);2-5H,1H3,(H,8,9,10);1H2/t16-,20+,21+,23-,30-;;/m1../s1 |
| Isomeric SMILES | CC1=CC=C(C=C1)S(=O)(=O)O.CC1(CCC2(CC1)[C@@]3([C@H]([C@@H](N2)C(=O)N[C@@H]4CC[C@H](OC4)C(=O)N)C5=C(C(=NC=C5)Cl)F)C6=C(C=C(C=C6)Cl)NC3=O)C.O |
| PubChem CID | 89051550 |
| Molecular Weight | 808.74 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Class | Carboxylic acids and derivatives |
| Subclass | Amino acids, peptides, and analogues |
| Intermediate Tree Nodes | Amino acids and derivatives - Alpha amino acids and derivatives |
| Direct Parent | Alpha amino acid amides |
| Alternative Parents | p-Methylbenzenesulfonates Tosyl compounds Azaspirodecane derivatives 1-sulfo,2-unsubstituted aromatic compounds Benzenesulfonyl compounds Indolines Pyrrolidinecarboxamides Polyhalopyridines 2-halopyridines Aralkylamines Oxanes Aryl chlorides Pyrans Aryl fluorides Organosulfonic acids Heteroaromatic compounds Sulfonyls Primary carboxylic acid amides Lactams Secondary carboxylic acid amides Oxacyclic compounds Azacyclic compounds Dialkylamines Dialkyl ethers Hydrocarbon derivatives Organofluorides Organochlorides Organic oxides Carbonyl compounds |
| Molecular Framework | Not available |
| Substituents | Alpha-amino acid amide - P-methylbenzenesulfonate - Azaspirodecane - Benzenesulfonate - Tosyl compound - Arylsulfonic acid or derivatives - Indole or derivatives - Benzenesulfonyl group - Dihydroindole - 1-sulfo,2-unsubstituted aromatic compound - Pyrrolidine carboxylic acid or derivatives - Pyrrolidine-2-carboxamide - Polyhalopyridine - Aralkylamine - 2-halopyridine - Toluene - Monocyclic benzene moiety - Oxane - Pyran - Pyridine - Benzenoid - Aryl halide - Aryl fluoride - Aryl chloride - Pyrrolidine - Organic sulfonic acid or derivatives - Organosulfonic acid or derivatives - Organosulfonic acid - Sulfonyl - Heteroaromatic compound - Lactam - Carboxamide group - Secondary carboxylic acid amide - Primary carboxylic acid amide - Organoheterocyclic compound - Azacycle - Oxacycle - Secondary amine - Dialkyl ether - Secondary aliphatic amine - Ether - Amine - Organooxygen compound - Carbonyl group - Organosulfur compound - Organic nitrogen compound - Organic oxygen compound - Organic oxide - Hydrocarbon derivative - Organonitrogen compound - Organohalogen compound - Organochloride - Organofluoride - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids. |
| External Descriptors | Not available |
| Solubility | DMSO : 50 mg/mL (61.82 mM; Need ultrasonic) |
|---|
